In various embodiments, the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy and, in particular, use of eicosapentaenoic acid ethyl ester in the manufacture of a medicament for reducing a risk of cardiovascular death, coronary revascularization, and/or unstable angina in a subject having metabolic syndrome and on stable statin therapy, wherein: (a) the subject has been identified as having dyslipidemia, as being on stable statin therapy, and as having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, optionally wherein said subject has established cardiovascular disease or has a high risk of developing cardiovascular disease； and (b) the medicament is formulated for daily administration in an amount to provide about 4 g of the eicosapentaenoic acid ethyl ester per day.
